selected publications
-
JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms.
Leukemia.
2024
Academic Article
GET IT
Times cited: 5 -
Mapping genotypes to chromatin accessibility profiles in single cells.
Nature.
2024
Academic Article
GET IT
Times cited: 27 -
Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2023
Academic Article
GET IT
Times cited: 1 -
Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome.
Blood advances.
2022
Academic Article
GET IT
Times cited: 9 -
Extensive Intracardiac and Deep Venous Thromboses in a Young Woman with Heparin-Induced Thrombocytopenia and May-Thurner Syndrome.
2017
GET IT
Times cited: 74 -
Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
Annals of hematology.
2017
Review
GET IT
Times cited: 18 -
Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAF(V600E) Melanoma.
The Journal of investigative dermatology.
2015
Letter
GET IT
Times cited: 54 -
A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging.
Science (New York, N.Y.).
2011
Academic Article
GET IT
Times cited: 357